CSIMarket
 


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 
 

INBP's Revenue Growth by Quarter and Year

Integrated Biopharma Inc's Revenue results by quarter and year




INBP Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter June - 13.27 17.06 13.54
III Quarter March - 15.63 17.07 13.63
II Quarter December - 14.59 14.26 14.20
I Quarter September 12.33 12.75 15.17 11.41
FY   12.33 56.24 63.56 52.78



INBP Revenue first quarter 2023 Y/Y Growth Comment
Integrated Biopharma Inc reported decrease in Revenue in the first quarter 2023 by -3.33% to $ 12.33 millions, from the same quarter in 2022.
The decrease in the first quarter 2023 Integrated Biopharma Inc's Revenue compares unfavorably to the Company's average Revenue growth of 7.82%.

Looking into first quarter 2023 results within Major Pharmaceutical Preparations industry 148 other companies have achieved higher Revenue growth. While Integrated Biopharma Inc' s Revenue decline of -3.33% ranks overall at the positon no. 2785 in the first quarter 2023.




INBP Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter June - -22.22 % 26 % -0.29 %
III Quarter March - -8.44 % 25.24 % -3.26 %
II Quarter December - 2.31 % 0.42 % 18.33 %
I Quarter September -3.33 % -15.95 % 32.95 % 10.78 %
FY   - -11.52 % 20.42 % 5.62 %

Financial Statements
Integrated Biopharma Inc's first quarter 2023 Revenue $ 12.33 millions INBP's Income Statement
Integrated Biopharma Inc's first quarter 2022 Revenue $ 12.75 millions Quarterly INBP's Income Statement
New: More INBP's historic Revenue Growth >>


INBP Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter June - -15.1 % -0.06 % -0.66 %
III Quarter March - 7.13 % 19.71 % -4.01 %
II Quarter December - 14.43 % -6 % 24.45 %
I Quarter September -7.11 % -25.26 % 12.04 % -15.98 %
FY (Year on Year)   - -11.52 % 20.42 % 5.62 %




Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #149
Healthcare Sector #419
Overall #2785

Revenue Y/Y Growth Statistics
High Average Low
34.26 % 7.82 % -22.96 %
(Sep 30 2016)   (Sep 30 2017)
Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #149
Healthcare Sector #419
Overall #2785
Revenue Y/Y Growth Statistics
High Average Low
34.26 % 7.82 % -22.96 %
(Sep 30 2016)   (Sep 30 2017)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Integrated Biopharma Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
24.47 % 1.44 % -25.25 %
(Dec 31 2019)  


INBP's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Integrated Biopharma Inc disclosed drop in Revenue from the previous quarter by -7.11% to $ 12.33 millions, from $ 13.27 millions declared in the previous reporting period.

It's not important problem, as I. Quarter Revenue frequently seem to dip in this quarter.

Within Major Pharmaceutical Preparations industry 187 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 3065.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #188
Healthcare Sector #495
Overall #3065
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #188
Healthcare Sector #495
Overall #3065
Revenue Q/Q Growth Statistics
High Average Low
24.47 % 1.44 % -25.25 %
(Dec 31 2019)  


INBP's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Integrated Biopharma Inc reported drop in Revenue from the forth quarter by -7.11% to $ 12.33 millions, from $ 13.27 millions declared in the previous reporting period.

It's not huge concern, as I. Quarter Revenue generally seem to slow in this quarter.

Within Major Pharmaceutical Preparations industry 187 other companies have achieved higher Revenue quarter on quarter growth. While Integrated Biopharma Inc's Revenue growth quarter on quarter, overall rank is 3065.


Integrated Biopharma Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Revenue 12 Months Ending $ 55.82 $ 56.25 $ 60.04 $ 61.48 $ 61.14
Y / Y Revenue Growth (TTM) -8.7 % -11.51 % 0 % 8.62 % 8.14 %
Year on Year Revenue Growth Overall Ranking # 2554 # 3084 # 2436 # 381 # 1903
Seqeuential Revenue Change (TTM) -0.76 % -6.31 % -2.34 % 0.55 % -3.81 %
Seq. Revenue Growth (TTM) Overall Ranking # 2776 # 3513 # 2674 # 447 # 2887




Cumulative Revenue growth Comment
Integrated Biopharma Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2022. If the fiscal year would end in Sep 30 2022, Integrated Biopharma Inc's annual Revenue decline would be -8.7% year on year to $56 millions.

In the Healthcare sector 397 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2554, from total ranking in previous quarter at 3084.

Revenue TTM Q/Q Growth Statistics
High Average Low
7.73 %
1.38 %
-6.31 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 148
Healthcare Sector # 398
Overall # 2554

Revenue TTM Y/Y Growth Statistics
High Average Low
346.88 %
29.03 %
-11.51 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 148
Sector # 419
S&P 500 # 2776
Cumulative Revenue growth Comment
Integrated Biopharma Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2022. If the fiscal year would end in Sep 30 2022, Integrated Biopharma Inc's annual Revenue fall would be -8.7% year on year to $56 millions.

In the Healthcare sector 397 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 2554, from total ranking in previous quarter at 3084.

Revenue TTM Q/Q Growth Statistics
High Average Low
7.73 %
1.38 %
-6.31 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 148
Healthcare Sector # 398
Overall # 2554

Revenue TTM Y/Y Growth Statistics
High Average Low
346.88 %
29.03 %
-11.51 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 148
Sector # 419
S&P 500 # 2776




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
INBP's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for INBP's Competitors
Revenue Growth for Integrated Biopharma Inc's Suppliers
Revenue Growth for INBP's Customers

You may also want to know
INBP's Annual Growth Rates INBP's Profitability Ratios INBP's Asset Turnover Ratio INBP's Dividend Growth
INBP's Roe INBP's Valuation Ratios INBP's Financial Strength Ratios INBP's Dividend Payout Ratio
INBP's Roa INBP's Inventory Turnover Ratio INBP's Growth Rates INBP's Dividend Comparisons



Companies with similar Revenue fall for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2022
Owens and Minor Inc -0.19%$ -0.191 millions
National Research Corporation-0.20%$ -0.201 millions
Livanova Plc-0.24%$ -0.241 millions
Healthcare Services Group Inc -0.27%$ -0.265 millions
Catalent Inc -0.29%$ -0.293 millions
Asensus Surgical Inc -0.31%$ -0.311 millions
Liquidia Corporation-0.43%$ -0.429 millions
Integra Lifesciences Holdings Corp-0.43%$ -0.432 millions
Pediatrix Medical Group Inc -0.62%$ -0.615 millions
China Pharma Holdings Inc -0.64%$ -0.642 millions
Acadia Pharmaceuticals Inc -0.68%$ -0.682 millions
Syneos Health Inc -0.89%$ -0.891 millions
Innovage Holding Corp -1.07%$ -1.070 millions
Procyon Corp-1.20%$ -1.200 millions
Precipio inc -1.38%$ -1.380 millions
Ati Physical Therapy Inc -1.40%$ -1.397 millions
Ocular Therapeutix Inc -1.55%$ -1.547 millions
Alpine Immune Sciences Inc -1.75%$ -1.750 millions
Surgalign Holdings Inc -1.79%$ -1.786 millions
Tenet Healthcare Corp-1.90%$ -1.900 millions
Teleflex Incorporated-1.92%$ -1.923 millions
Novocure Limited-1.95%$ -1.952 millions
Dynatronics Corporation-2.01%$ -2.014 millions
Royalty Pharma Plc-2.10%$ -2.101 millions
National Healthcare Corp-2.13%$ -2.130 millions
Fonar Corporation-2.27%$ -2.271 millions
Psychemedics Corp-2.35%$ -2.353 millions
Escalon Medical Corp -2.63%$ -2.626 millions
Lifevantage Corp-2.72%$ -2.724 millions
West Pharmaceutical Services Inc -2.77%$ -2.774 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

NOG's Profile

Stock Price

NOG's Financials

Business Description

Fundamentals

Charts & Quotes

NOG's News

Suppliers

NOG's Competitors

Customers & Markets

Economic Indicators

NOG's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071